Halberd Corporation Files for Patent Protection on Enhanced Nasal Spray to Prevent Covid-19
Jackson Center, PA, November 9, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, “Nasal Spray to Prevent the Transmission of Covid-19,” discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies. This application builds on, and is an improvement to an earlier provisional patent application, “Nasal Spray to Prevent the Transmission of Covid-19 Between Humans.” Multiple medical ...
Halberd Corp. Develops Second Covid-19 Antibody for Enhanced Nasal Spray and Doubles Performance of New Class of Antibody
Jackson Center, PA, November 5, 2020 – Halberd Corporation (OTC PINK: "HALB") reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberd’s continuing work on its new class of antibody doubles the performance capacity of a key functional parameter. Dr. Mitchell S. Felder, a Halberd consultant, filed a provisional patent application for a nasal spray utilizing ...
Halberd Corp. CEO Interviewed on Money TV
In Case You Missed It - Mr. Hartman discusses recent accomplishments and new opportunities. Jackson Center, PA, November 2, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided an update on the company’s latest activities, and new efforts underway. Mr. Baillargeon began the interview by asking how Halberd decided on its university research partner. Mr. ...
Halberd Corp. Development Efforts Transcend Covid-19 Prevention, Diagnostics & Therapeutics
Jackson Center, PA, October 29, 2020 – Halberd Corporation (OTC PINK: "HALB") today provided insight concerning its strategic plans beyond developing unique antibodies which form the basis of their current all-out efforts to generate products and processes to prevent, diagnose and treat Covid-19. These strategic plans are designed to benefit people well after Covid-19 is no longer an issue. William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “Currently, we are dedicating our maximum ...
Halberd Corp. Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies
Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters. The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney on the Halberd account is Dr. Darwin King, Esq., who has extensive experience in dealing with intellectual property matters in ...
ICYMI — Halberd Corporation Discusses The Development of New Class of COVID-19 Antibody with The Stock Day Podcast
In Case You Missed It Phoenix, Arizona–(Newsfile Corp. – October 22, 2020) – The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) (“the Company”), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. CEO of the Company, Bill Hartman, joined Stock Day host Everett Jolly. Jolly began the interview by asking about Hartman’s transition from his former position as the CEO of Premier Biomedical to ...